Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia

Eur Arch Psychiatry Clin Neurosci. 1999:249 Suppl 2:II1-II14. doi: 10.1007/pl00014165.
No abstract available

Publication types

  • Meta-Analysis

MeSH terms

  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / therapeutic use*
  • Benzodiazepines
  • Dose-Response Relationship, Drug
  • Humans
  • Imidazoles / administration & dosage
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Indoles / administration & dosage
  • Indoles / adverse effects
  • Indoles / therapeutic use*
  • Olanzapine
  • Pirenzepine / administration & dosage
  • Pirenzepine / adverse effects
  • Pirenzepine / analogs & derivatives*
  • Pirenzepine / therapeutic use
  • Risk Assessment
  • Risperidone / administration & dosage
  • Risperidone / adverse effects
  • Risperidone / therapeutic use*
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Imidazoles
  • Indoles
  • Benzodiazepines
  • Pirenzepine
  • sertindole
  • Risperidone
  • Olanzapine